Your browser doesn't support javascript.
loading
Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery.
Dee, Edward Christopher; Ng, Victor C; O'Reilly, Eileen M; Wei, Alice C; Lobaugh, Stephanie M; Varghese, Anna M; Zinovoy, Melissa; Romesser, Paul B; Wu, Abraham J; Hajj, Carla; Cuaron, John J; Khalil, Danny N; Park, Wungki; Yu, Kenneth H; Zhang, Zhigang; Drebin, Jeffrey A; Jarnagin, William R; Crane, Christopher H; Reyngold, Marsha.
Afiliación
  • Dee EC; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Ng VC; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • O'Reilly EM; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Wei AC; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Lobaugh SM; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Varghese AM; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Zinovoy M; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Romesser PB; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Wu AJ; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Hajj C; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Cuaron JJ; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Khalil DN; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Park W; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Yu KH; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Zhang Z; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Drebin JA; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Jarnagin WR; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Crane CH; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Reyngold M; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
J Clin Med ; 13(9)2024 Apr 30.
Article en En | MEDLINE | ID: mdl-38731159
ABSTRACT

Introduction:

The rate of isolated locoregional recurrence after surgery for pancreatic adenocarcinoma (PDAC) approaches 25%. Ablative radiation therapy (A-RT) has improved outcomes for locally advanced disease in the primary setting. We sought to evaluate the outcomes of salvage A-RT for isolated locoregional recurrence and examine the relationship between subsequent patterns of failure, radiation dose, and treatment volume.

Methods:

We conducted a retrospective analysis of all consecutive participants who underwent A-RT for an isolated locoregional recurrence of PDAC after prior surgery at our institution between 2016 and 2021. Treatment consisted of ablative dose (BED10 98-100 Gy) to the gross disease with an additional prophylactic low dose (BED10 < 50 Gy), with the elective volume covering a 1.5 cm isotropic expansion around the gross disease and the circumference of the involved vessels. Local and locoregional failure (LF and LRF, respectively) estimated by the cumulative incidence function with competing risks, distant metastasis-free and overall survival (DMFS and OS, respectively) estimated by the Kaplan-Meier method, and toxicities scored by CTCAE v5.0 are reported. Location of recurrence was mapped to the dose region on the initial radiation plan.

Results:

Among 65 participants (of whom two had two A-RT courses), the median age was 67 (range 37-87) years, 36 (55%) were male, and 53 (82%) had undergone pancreaticoduodenectomy with a median disease-free interval to locoregional recurrence of 16 (range, 6-71) months. Twenty-seven participants (42%) received chemotherapy prior to A-RT. With a median follow-up of 35 months (95%CI, 26-56 months) from diagnosis of recurrence, 24-month OS and DMFS were 57% (95%CI, 46-72%) and 22% (95%CI, 14-37%), respectively, while 24-month cumulative incidence of in-field LF and total LRF were 28% (95%CI, 17-40%) and 36% (95%CI 24-48%), respectively. First failure after A-RT was distant in 35 patients (53.8%), locoregional in 12 patients (18.5%), and synchronous distant and locoregional in 10 patients (15.4%). Most locoregional failures occurred in elective low-dose volumes. Acute and chronic grade 3-4 toxicities were noted in 1 (1.5%) and 5 patients (7.5%), respectively.

Conclusions:

Salvage A-RT achieves favorable OS and local control outcomes in participants with an isolated locoregional recurrence of PDAC after surgical resection. Consideration should be given to extending high-dose fields to include adjacent segments of at-risk vessels beyond direct contact with the gross disease.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza